Trials / Terminated
TerminatedNCT01806649
BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy
A Phase II Study of BKM120; a Pan-PI3K Inhibitor in Patients With Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Prince of Songkla University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
There is a need for more effective therapy for patients with esophageal squamous cell carcinoma who developed disease progression after first line therapy. Currently, there is no standard second-line therapy for this disease. BKM-120 is a pan-PI3K inhibitor currently tested in clinical trials. In a cellular model of oral-esophageal carcinogenesis, it has shown that EGFR overexpression activated PI3/AKT pathway. Therfore, there is interest to see the efficacy and safety of BKM120 in this setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BKM120 |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2016-04-30
- Completion
- 2016-04-30
- First posted
- 2013-03-07
- Last updated
- 2021-10-11
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT01806649. Inclusion in this directory is not an endorsement.